Experience With Lacosamide in a Series of Children With Drug-Resistant Focal Epilepsy


Autoria(s): GUILHOTO, Laura Maria de Figueiredo Ferreira; LODDENKEMPER, Tobias; GOOTY, Vasu D.; ROTENBERG, Alexander; TAKEOKA, Masanori; DUFFY, Frank H.; COULTER, David; URION, David; BOURGEOIS, Blaise F.; KOTHARE, Sanjeev V.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2011

Resumo

We report our pediatric experience with lacosarnide, a new antiepileptic drug, approved by the US Food and Drug Administration as adjunctive therapy in focal epilepsy in patients more than 17 years old. We retrospectively reviewed charts for lacosamide use and seizure frequency outcome in patients with focal epilepsy (Wilcoxon signed rank test). Sixteen patients (7 boys) were identified (median dose 275 mg daily, 4.7 mg/kg daily; mean age 14.9 years, range 8-21 years). Patients were receiving a median of 2 antiepileptic drugs (interquartile range [IQR] 1.7-3) in addition to having undergone previous epilepsy surgery (n = 3), vagus nerve stimulation (n = 9), and ketogenic diet (n = 3). Causes included structural (encephalomalacia and diffuse encephalitis, 1 each; stroke in 2) and genetic abnormalities (Aarskog and Rett syndromes, 1 each) or cause not known (n = 10). Median seizure frequency at baseline was 57 per month (IQR 7-75), and after a median follow-up of 4 months (range 1-13 months) of receiving lacosamide, it was 12.5 per month (IQR 3-75), (P < 0.01). Six patients (37.5%; 3 seizure free) were classified as having disease that responded to therapy (>= 50% reduction seizure frequency) and 10 as having disease that did not respond to therapy (<50% in 3; increase in 1; unchanged in 6). Adverse events (tics, behavioral disturbance, seizure worsening, and depression with suicidal ideation in 1 patient each) prompted lacosamide discontinuation in 4/16 (25%). This retrospective study of 16 children with drug-resistant focal epilepsy demonstrated good response to adjunctive lacosamide therapy (median seizure reduction of 39.6%; 37.5% with >= 50% seizure reduction) without severe adverse events. (C) 2011 Elsevier Inc. All rights reserved.

Brazilian government[4225-09-0]

Identificador

PEDIATRIC NEUROLOGY, v.44, n.6, p.414-419, 2011

0887-8994

http://producao.usp.br/handle/BDPI/26906

10.1016/j.pediatrneurol.2011.12.003

http://dx.doi.org/10.1016/j.pediatrneurol.2011.12.003

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

Relação

Pediatric Neurology

Direitos

restrictedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #PARTIAL-ONSET SEIZURES #RANDOMIZED CONTROLLED-TRIAL #ANTIEPILEPTIC DRUGS #INTRAVENOUS LACOSAMIDE #ORAL LACOSAMIDE #ADJUNCTIVE LACOSAMIDE #STATUS EPILEPTICUS #EFFICACY #THERAPY #SAFETY #Clinical Neurology #Pediatrics
Tipo

article

original article

publishedVersion